Selenium nanoparticles activate selenoproteins to mitigate septic lung injury through miR-20b-mediated RORγt/STAT3/Th17 axis inhibition and enhanced mitochondrial transfer in BMSCs DOI Creative Commons
Wan‐Jie Gu,

Fengzhi Zhao,

Wei Huang

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: March 20, 2025

Sepsis-induced acute lung injury (ALI) remains a critical clinical challenge with complex inflammatory pathogenesis. While bone marrow mesenchymal stem cells (BMSCs) demonstrate therapeutic potential through anti-inflammatory and cytoprotective effects, their age-related functional decline limits utility. This study developed chitosan-functionalized selenium nanoparticles (SeNPs@CS, 100 nm) to rejuvenate BMSCs miR-20b-mediated selenoprotein biosynthesis. Mechanistic investigations revealed that SeNPs@CS-treated exhibited enhanced mitochondrial transfer capacity, delivering mitochondria damaged alveolar epithelial (AECII) for cellular repair. Concurrently, miR-20b upregulation suppressed the RORγt/STAT3/Th17 axis, reducing pro-inflammatory Th17 cell differentiation in CD4+ T lymphocytes. The dual-target mechanism integrates immunomodulation via pathway inhibition rejuvenation therapy, representing paradigm-shifting approach ALI management. These engineered mitigated markers murine models, demonstrating superior efficacy conventional BMSC therapies. Our findings establish SeNPs@CS-modified as novel platform combining nanotechnology-enhanced engineering precision immunometabolic regulation, providing new avenues treatment of sepsis-induced ALI.

Language: Английский

Selenium nanoparticles activate selenoproteins to mitigate septic lung injury through miR-20b-mediated RORγt/STAT3/Th17 axis inhibition and enhanced mitochondrial transfer in BMSCs DOI Creative Commons
Wan‐Jie Gu,

Fengzhi Zhao,

Wei Huang

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: March 20, 2025

Sepsis-induced acute lung injury (ALI) remains a critical clinical challenge with complex inflammatory pathogenesis. While bone marrow mesenchymal stem cells (BMSCs) demonstrate therapeutic potential through anti-inflammatory and cytoprotective effects, their age-related functional decline limits utility. This study developed chitosan-functionalized selenium nanoparticles (SeNPs@CS, 100 nm) to rejuvenate BMSCs miR-20b-mediated selenoprotein biosynthesis. Mechanistic investigations revealed that SeNPs@CS-treated exhibited enhanced mitochondrial transfer capacity, delivering mitochondria damaged alveolar epithelial (AECII) for cellular repair. Concurrently, miR-20b upregulation suppressed the RORγt/STAT3/Th17 axis, reducing pro-inflammatory Th17 cell differentiation in CD4+ T lymphocytes. The dual-target mechanism integrates immunomodulation via pathway inhibition rejuvenation therapy, representing paradigm-shifting approach ALI management. These engineered mitigated markers murine models, demonstrating superior efficacy conventional BMSC therapies. Our findings establish SeNPs@CS-modified as novel platform combining nanotechnology-enhanced engineering precision immunometabolic regulation, providing new avenues treatment of sepsis-induced ALI.

Language: Английский

Citations

0